CRISPR, Gene Editing, and Computing on DNA

  • Print

A number of biotech stocks got hit last month when a controversial paper was released throwing doubt on the new and extremely promising gene-editing technique called CRISPR. Ian Haydon, a doctoral student at the University of Washington, joins FS Insider to discuss the paper, why CRISPR is such a big deal, as well as the fascinating merger taking place between biochemistry and computer science.

For full access to the interview, please log in and click the MP3 button or click here to subscribe. Questions? Check out our FAQ page.

Related:
CRISPR controversy raises questions about gene-editing technique
Is CRISPR Gene Editing Moving Ahead Too Quickly?
Synthetic Biology Expands and Grows
Synthetic Cells Have Passed A Turing Test

CLICK HERE to subscribe to the free weekly Best of Financial Sense Newsletter .

About Cris Sheridan

Quantcast